| Private Placement / Financing Transactions
Koios Medical: The company raised $130 million of venture funding in the form of convertible debt from undisclosed investors on June 24, 2024. The company is a developer of an ultrasound image analysis platform intended to offer early disease detection and diagnosis.
Endogenex: The company raised $88 million of Series C venture funding from Mayo Clinic Ventures, Intuitive Ventures and Orlando Health Ventures on June 24, 2024. Santé Ventures, Longitude Capital, Lumira Ventures, Hatteras Venture Partners and other undisclosed investors also participated in the round. The company is a developer of a novel endoscopic procedure designed to treat diabetes.
Exsilio: The company raised $82 million of Series A venture funding in a deal led by Novartis Venture Fund and Delos Capital Partners on June 25, 2024. CRISPR Therapeutics, Arc Ventures, The Invus Group, OrbiMed, Insight Partners, JPMorgan Life Sciences Private Capital, Innovation Endeavors, Arc Ventures (United States) and Deep Insight (Herzliya) also participated in the round. The company is a manufacturer of genomic medicines for the treatment of a broad range of diseases.
UroMems: The company raised $47 million of Series C venture funding in a deal led by Crédit Mutuel Innovation on June 25, 2024. HIL-INVENT, Financiere Arbevel, European Innovation Council Fund, Wellington Partners, b2venture, Supernova Invest and Bpifrance also participated in the round. The company is a developer of an active, implantable medical device for urinary incontinence.
RareCyte: The company raised $20 million of venture funding in a deal led by Arboretum Ventures, F-Prime Capital and Forest Road Company on June 27, 2024. Agilent Technologies, HealthQuest Capital, 5AM Ventures, Sheatree Capital and GKCC also participated in the round. The company is a developer of a cell discovery kit designed for the detection of circulating tumor cells.
VenoStent: The company raised $20 million of Series A venture funding in a deal led by IAG Capital Partners and Good Growth Capital on June 27, 2024, putting the company’s pre-money valuation at $26.1 million. Alumni Ventures, Wealthing VC Club, Wealthing VC Fund, Texas Medical Center, SNR, Norwest Venture Partners and Baylor Angel Network also participated in the round. The company is a developer of a biomedical engineering technology designed to improve the quality and length of life for dialysis patients.
Neonc Technologies: The company raised $18.5 million of venture funding from undisclosed investors on June 26, 2024. NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases.
Augustine Therapeutics: The company raised EUR 17 million of Series A venture funding in a deal led by Asabys Partners on June 26, 2024. Eli Lilly and Company, CMT Research Foundation, AdBio partners, V-Bio Ventures, University of Leuven, VIB and Participatiemaatschappij Vlaanderen also participated in the round. The company is a developer of therapeutic drugs designed to treat neuromuscular and neurodegenerative diseases.
Holoclara: The company raised $16 million of Series A venture funding in a deal led by Bold Capital Partners on June 27, 2024. Endurance28, Horizons Ventures, Tarrasque, Freeflow Ventures, and other undisclosed angel investors also participated in the round. The company is a provider of immunotherapy services intended to bring relief to people suffering from autoimmune disorders.
Vibronix: The company raised an estimated CNY 100 million of Series A+ venture funding in a deal led by Tao Capital on June 24, 2024. Founder H Fund and Frees Fund also participated in the round. The company is a developer of an advanced imaging technology designed to commercialize sensor devices for the diagnosis of diseases and treatments.
Esper Bionics: The company raised $5 million of venture funding in a deal led by YZR Capital on June 28, 2024. EBRD Venture Capital Investment Programme and u.ventures also participated in the round. The company is a developer of human augmentation robotic limbs and controllers designed for people with limb differences.
Sonia: The company raised $3.4 million of venture funding from Pioneer Fund, Moonfire and Rebel Fund on June 27, 2024. SBXi also participated in the round. The company is an operator of a cognitive therapy-based platform intended to improve mental health.
BioMap: The company raised an undisclosed amount of venture funding from Hong Kong investment on June 24, 2024. The company is a developer of AI foundation models designed to drive new drug research and development.
CipherHealth: The company received an undisclosed amount of development capital from Atalaya Capital Management on June 26, 2024. The company is a developer of patient communication, engagement, and care coordination software intended for clients in the United States.
Cx Precision Medicine: The company is in the process of raising $4 million venture funding on June 26, 2024. The company is a developer of neurodegenerative therapeutics designed to develop blood-protein screening technology and companion diagnostics for therapeutic agents.
Imvaria: The company raised an undisclosed amount of venture funding in the form of Convertible debt from Mayo Clinic Ventures on June 26, 2024. The company is a developer of digital biomarkers designed to enhance patient outcomes.
Otologic.Tech: The company is in the process of raising an undisclosed amount of venture funding on June 25, 2024. The company is a developer of artificial intelligence (AI) tools designed to help clinicians diagnose ear ailments.
Panda Surgical: The company is in the process of raising Pre-Series A venture funding on June 25, 2024. The company is a developer of robotics neurosurgery systems designed to increase the efficacy and safety of minimally invasive neurosurgery.
Pear Suite: The company raised an undisclosed amount of venture funding from AARP, Flare Capital Partners and Rock Health Capital on June 24, 2024. California Health Care Foundation also participated in the round. The company is a developer of a cloud-based care navigation platform that enables anyone—community health workers, peer specialists, representatives, and volunteers—to better assess and address the social drivers of health.
Renerva: The company is in the process of raising $1.5 million of venture funding on June 27, 2024. The company is a developer of medical device implant surgical devices to facilitate nerve repair, recovery, and storage.
|
